Nordicus Partners Corporation announced the appointment of Elizabeth Addonizio as an independent member of its Board of Directors, effective September 1, 2026. The appointment fills a vacancy created by the resignation of Andrew Ritter. The Company stated that the addition of Ms. Addonizio strengthens board independence and financial expertise.
Ms. Addonizio is a finance professional with 25 years of experience in venture and private equity investing and investment banking. She has spent the past decade investing with families and entrepreneurs in U.S.-based, early-stage companies and has served as a fractional CFO across diverse sectors. Previously, she was a managing director at Cranemere, where she evaluated middle-market private equity investments and served on the Investment Committee. Earlier in her career, she worked at Morgan Stanley advising on more than $25 billion in M&A, leveraged finance, and equity transactions.
In addition to her finance career, Ms. Addonizio has served as an officer in the U.S. Navy Reserve since 2004. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. She has led teams in support of U.S. European Command, ONI, Naval Criminal Investigative Service (NCIS), and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the then Commander of U.S. Central Command, General David Petraeus.
The Company executed a Directors Agreement with Ms. Addonizio on September 1, 2026. Under the agreement, she will receive an annual cash retainer of $10,000, payable in two installments per calendar year. Additionally, she will receive options to purchase 25,000 shares of the Company’s common stock at $4.09 per share. All options are fully vested on the date of grant and are issued as Incentive Stock Options under the Company’s 2024 Stock Incentive Plan.
Nordicus Partners Corporation is a U.S.-based biotech company focusing on acquiring and developing drugs from innovative biotech companies in the Nordics. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. Its scientific foundation targets inflammation and immune modulation. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company, and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company.
